These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Performance validation of a third-generation allergen-specific IgE assay in the clinical laboratory: interlaboratory and intermethod comparison.
    Author: Li TM, Fu P, Zic V.
    Journal: Clin Chim Acta; 2005 Nov; 361(1-2):199-205. PubMed ID: 15996649.
    Abstract:
    BACKGROUND: Allergen-specific IgE (sIgE) measurements are used to help identify causative allergenic agents and to determine the degree of sensitization to facilitate treatment decisions. We examined the performance of a new third-generation chemiluminescent enzyme immunoassay for allergen-specific IgE (sIgE) on the continuous random access Immulite 2000 system. METHODS: Detection limit and dilutional linearity were determined. Within-run and total precision were assessed according to the NCCLS EP5 guideline. Interlaboratory comparison of the new Immulite 2000 third-generation allergen-specific IgE assay was performed, as well as intermethod comparison against the Pharmacia FEIA, a second-generation assay. RESULTS: The detection limit was <0.1 kU/l. Dilutional linearity held from 100 down to 0.2 kU/l. Regression analysis of the interlaboratory comparison results yielded: Immulite 2000(Laboratory 1)=1.07 Immulite 2000(Laboratory 2)+0.18 kU/l; r=0.98, n=3588 results. Intermethod comparison showed the following: Immulite 2000=0.83 (Pharmacia FEIA)+0.42 kU/l; r=0.79, n=512 results. Bland-Altman analysis of the interlaboratory and intermethod comparisons indicated no systematic bias. CONCLUSIONS: We confirmed the reported performance characteristics of the third-generation sIgE assay and found reasonably good interlaboratory and intermethod agreement. The extended range capability of the third-generation assay provides a new tool for investigating cutoffs and trends in childhood allergy disease progression at concentrations <0.35 kU/l.
    [Abstract] [Full Text] [Related] [New Search]